Literature DB >> 20120431

Tamiflu: what dermatologists need to know.

Kendra Gail Bergstrom1.   

Abstract

This article is a review of this winter's common infections and their treatments. As infectious agents become more aggressive and more resistant, new medications are needed to fight them. The recent outbreak of the H1N1 ("swine flu") influenza strain has increased, by several-fold, the use of the oral antiviral Tamiflu (oseltamivir) and Relenza (zenavimir). -As resistant skin and soft-tissue infections increase in frequency, the use of newer antibiotics is becoming more common. This article reviews the use and cutaneous side effects of antivirals and new antibiotics with a focus on those relevant to the dermatologist.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20120431

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  1 in total

Review 1.  Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist.

Authors:  Antonio Martinez-Lopez; Carlos Cuenca-Barrales; Trinidad Montero-Vilchez; Alejandro Molina-Leyva; Salvador Arias-Santiago
Journal:  J Am Acad Dermatol       Date:  2020-08-07       Impact factor: 11.527

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.